Alercell Inc has announced a private offering aiming to raise $1.5 million, as detailed in its recent SEC filing. The biotechnology company has already sold $35,000 of the offering, which allows for participation from non-accredited investors. This move is significant as it demonstrates Alercell's efforts to secure funding for its operations and growth.
Founded in Montana, Alercell Inc operates in the biotechnology sector. The company, which has no reported revenues, is incorporated in Montana and is identified under the Central Index Key (CIK) number 0002160842. The filing, dated October 19, 2026, is categorized under the SEC Act of 1933.
The SEC filing reveals that the offering is structured under Rule 506(b), which provides a “safer harbor” for private offerings. The total amount offered is $1.5 million, with a minimum investment accepted of $5,000. Alercell has indicated that it has three investors already participating in the offering.
According to the filing, there are no sales commissions or finders' fees associated with this offering. The total remaining amount available for sale is $1,465,000. The filing also specifies that the company has not yet used any gross proceeds from the offering.
This fundraising initiative may affect potential investors, especially those who are non-accredited, as it opens the door for broader participation in Alercell's financial future. The biotechnology industry may also observe this development closely, as similar companies often seek innovative ways to attract investment.
Details were not available in the SEC filing regarding the next steps following this offering. However, the company’s ongoing efforts to raise capital could lead to further developments in the near future.